Pharmaceutical Stocks
Recent market-moving SEC filings and news across pharmaceutical companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a pharmaceutical company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Biotech StocksMedical Device StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
Cumberland's First Post-Divestiture Quarter: $7.6M Loss, $3.9M Cash, and $100M Proceeds Received After Quarter-End
Canopy Growth Puts Reverse Split, Auditor Change, and Pay Plan to Shareholder Vote
IM Cannabis Raises US$250K via Convertible Note and 2M+ Warrants — Deeply Dilutive Terms
Merck Q2 2026: Revenue Beats, Guidance Raised, but GAAP Loss on Terns Charge; Keytruda and Winrevair Drive Growth
Canopy Growth Changes Auditors Amidst Ongoing Financial Reporting Challenges
FDA Authorizes Elanco's CLiK Extra Spray to Combat Screwworm Outbreak
Cortrophin Gel Guidance Slashed, ANI Pharma Tumbles 6%
Lilly Crushes Q2: Revenue Soars 48%, Guidance Raised to $87B
Canopy Growth Q1 Revenue Climbs 13%, Loss Shrinks 68% — Adjusted EBITDA Loss Cut to C$3.2M
ANI Pharmaceuticals Posts Record Q2 Revenue of $266M, a 26% YoY Jump, and Reaffirms Full-Year Guidance
ANI Pharmaceuticals Posts Record Q2 Revenue of $266M and Reaffirms Full-Year Outlook
Canopy Growth Q1 Revenue Jumps 13%, Loss Narrows 68% on Broad-Based Strength
Canopy Growth Q1 FY2027: Revenue Climbs 13%, Loss Shrinks, but Acreage Default and Material Weakness Linger
Amneal reports strong Q2 earnings, shifts to positive equity, but faces new operational and tariff risks
Amphastar Q2 Revenue Climbs 5% to $183.9M, GAAP EPS $0.67; BAQSIMI Milestone Triggers $100M Payment
SIGA Q2 Revenue Halves as BARDA Contract Winds Down; Cash Drops to $118M
Organogenesis Taps $75M At-the-Market Equity Program to Shore Up Liquidity
Organogenesis Launches $75M ATM Equity Program After Q2 Revenue Plunge and Guidance Cut
Organogenesis Q2 Revenue Plunges 58%, Loss Widens to $96M; Guidance Slashed
Zhengye Biotechnology Regains Nasdaq Compliance, Removing Delisting Risk
Ironwood Swings to $92M H1 Profit on 74% Revenue Surge, Initiates Pivotal Apraglutide Trial
Amphastar Q2 Revenue Hits $183.9M, BAQSIMI® Milestone Triggers $100M Lilly Payment
Zoetis Q2 2026: Flat Revenue as U.S. Companion Animal Weakness Meets Restructuring and Legal Headwinds
Zoetis Slashes 2026 Guidance by 10%, U.S. Pet Sales Plunge 11%
Viatris Sells Tyrvaya for Up to $100M, Lifts 2026 Guidance
Sonoma Pharma Q1 Revenue Jumps 60% to $6.4M, Nears Breakeven
Sonoma Nears Breakeven as Revenue Jumps 60%, But Nasdaq Delisting Risk Looms
Lantheus Q2 Revenue Beats, But Guidance Suspended Amid $8B Curium Buyout
MIRA De-Risks Obesity Drug Dose Selection with Positive 7-Day Dog Study for SKNY-1
Viatris Reports Strong Q2, Raises Full-Year Guidance, and Announces Key Product Approvals
Viatris Beats Q2 Estimates, Lifts 2026 Profit Outlook on Branded Drug Strength
Lantheus Q2 Revenue Beats at $388M, Adjusted EPS $1.55; Guidance Pulled Amid $8B Curium Buyout
Collegium Q2: Azstarys Integration Lifts Revenue, but Acquisition Costs Drag Bottom Line into the Red
Collegium Q2 Revenue Tops $200M, but Nucynta Pricing Pressure Forces Full-Year Guidance Cut
Cronos Group Swings to Q2 Profit on 58% Revenue Surge; New Anti-Dumping Probe Looms
Cronos Group Posts Record Q2 Revenue, Swings to Profit, and Flags New Israeli Anti-Dumping Probe
Collegium Q2 Revenue Hits $199.9M, JORNAY PM Surges 41%, Raises AZSTARYS Outlook
Ironwood Lifts 2026 Outlook, Signaling Stronger Growth
Zoetis Issues 2026 Adj EPS Guidance of $6.15-$6.25
Lantheus Q2 Beats Across the Board, But Suspends Guidance Amid $8B Curium Buyout